NCT01125475

A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects

A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects: the ScanSmart Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 61 (actual)
• Sponsor: Merck KGaA, Darmstadt, Germany · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The primary objective is to determine adherence to Rebif® New Formulation administered by RebiSmart during 12 weeks of therapy in patients with RRMS.

Conditions

• Relapsing Remitting Multiple Sclerosis (RRMS)

Interventions

Type	Name	Description
DEVICE	RebiSmart	Treatment with Rebif New Formulation using RebiSmart.

Timeline

• Start date: 2010-08-01
• Primary completion: 2012-03-01
• First posted: 2010-05-18
• Last updated: 2014-07-16

Locations

1 site across 1 country: Norway